Adverse effects of Filgrastim during pregnancy is unknown. Studies in animals show that Filgrastim increases the incidence of embryonary losses but not of malformations. The relation between the therapeutic benefit and the possible fetal risks should be assessed before using Filgrastim in pregnant women. It is unknown if Filgrastim is secreted in maternal milk thus its use is not recommended in breastfeeding women.